Ipsen (LTS:0MH6) Total Equity: €4,337 Mil (As of Dec. 2025)


LTS:0MH6 Ipsen SA LTS:0MH6
94 GF Score
Price €170.25
GF Value €133.79
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ipsen Total Equity?

Ipsen LTS:0MH6 -0.29% 94 Total Equity is €4,337 Mil as of Dec. 2025. GuruFocus rates LTS:0MH6 with a GF Score™ of 94/100 and a GF Value™ of €133.79 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Ipsen's total equity for the quarter that ended in Dec. 2025 was €4,337 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Ipsen Total Equity Historical Data

* Premium members only.

The historical data trend for Ipsen's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen Total Equity Chart

Ipsen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,737.70 3,343.40 3,823.80 4,181.80 4,336.80

Ipsen Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,823.80 4,046.10 4,181.80 4,230.40 4,336.80
LTS:0MH6
94GF Score
Ipsen SA LTS:0MH6
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipsen Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Ipsen's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=6937.8-2601
=4,337

Ipsen's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=6937.8-2601
=4,337

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €4,337 Mil mean?
Ipsen (LTS:0MH6) has a Total Equity of €4,337 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Ipsen and its competitors.
Is Ipsen's Total Equity too high?
Ipsen's current Total Equity is €4,337 Mil. Overall, Ipsen has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipsen's Total Equity compare to ZTS and UTHR?
Ipsen's Total Equity of €4,337 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Ipsen and its competitors. Ipsen's current Total Equity is €4,337 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Based on GuruFocus' analysis, Ipsen (LTS:0MH6) is currently considered Modestly Overvalued. The stock's GF Value™ is €133.79, compared to a current price of €170.25 — trading 27.3% above its estimated fair value. The current Total Equity is €4,337 Mil. Ipsen's overall GF Score™ is 94/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Ipsen (LTS:0MH6), the current Total Equity is €4,337 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipsen (LTS:0MH6) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €170.25 is trading 27.3% above its estimated GF Value™ of €133.79. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for LTS:0MH6:

  • Total Equity: €4,337 Mil
  • GF Value™: €133.79 vs. price of €170.25 (27.3% above fair value)
  • GF Score™: 94/100 with 7 warning signs

No single metric tells the full story. See the LTS:0MH6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
94GF Score

Get the complete analysis for LTS:0MH6

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€170.25
Price
€133.79
GF Value